concentrations in both pericardial fluid and saliva by 24 h. The pilot study highlights the importance of inflammatory cytokines to drive the progression of pericarditis and its complication and also suggests the possibility to monitor the early effect of therapy by their testing from plasma or saliva.
Targeting the treatment to specific cytokines is an emerging option for refractory recurrent pericarditis with corticosteroid dependence and colchicine resistance, where treatment with anakinra (an IL 1 antagonist) is successful to reach remission and allow corticosteroids withdrawal [8, 9] .
